
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is well-positioned in the market due to its unique product, the iLet Bionic Pancreas, which aims to improve the treatment of diabetes for patients. The company's recent sales growth, increased guidance, and expansion of its sales force highlight the strong potential for revenue growth in the coming years. With steady beats and raises to results and guidance and potential upcoming momentum around the company's semi-durable patch pump, Beta Bionics is a compelling investment opportunity for those with a positive outlook on the company's potential.
Bears say
Beta Bionics is facing challenges in potential commercialization with their iLet Bionic Pancreas device as demonstrated through their lowered sales outlook for ’27 and increasing cash burn. Despite a strong first quarter and positive commentary on their Mint patch product, the stock is under pressure due to broader negative sentiment towards small cap med tech companies. While the iLet Bionic Pancreas has the potential to improve outcomes for PWDs, the limited market and competitive landscape may hinder its success and make it a risky investment at this time.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares